Stay updated on Pembrolizumab for Rare Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.
Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check20 days agoChange DetectedThe web page has been updated to include detailed information about a phase II clinical trial studying the efficacy of pembrolizumab in treating patients with rare tumors. Key elements such as study objectives, eligibility criteria, and treatment protocols have been added, enhancing the core content significantly.SummaryDifference100%
- Check27 days agoChange DetectedThe web page has undergone significant content removal, particularly regarding detailed information about a phase II clinical trial for pembrolizumab, including study objectives, eligibility criteria, and treatment protocols.SummaryDifference89%
- Check34 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check41 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check48 days agoChange DetectedDifference0.2%
Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.